newsfilter
← Latest News
GlobeNewswire·

Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates

Initiated two parallel, adequately-powered Phase 2 trials of emraclidine in schizophrenia with data expected 1H 2024 Phase 1 trial of emraclidine to be initiated by year-end to support future development in Alzheimer's disease psychosis Panic diso